Quick Answer
AEON Biopharma, Inc. reported Diluted EPS of $3.95 per share (loss) for fiscal year 2025.
AEON Biopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.95 | -105.4% |
| 2024 | $72.93 | +19292.1% |
| 2022 | -$0.38 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.39 | +96.5% | +35.0% |
| June 30, 2025 | -$0.60 | -100.2% | -126.3% |
| March 31, 2025 | $2.28 | +101.0% | +120.3% |
| September 30, 2024 | -$11.24 | -40.3% | -103.7% |
| June 30, 2024 | $304.00 | +276463.6% | +233.4% |
| March 31, 2024 | -$227.87 | -175184.6% | -2744.8% |
| September 30, 2023 | -$8.01 | -9912.5% | -3905.0% |
| July 31, 2023 | -$0.20 | — | -81.8% |
- AEON Biopharma, Inc. showed a decrease of -105.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, AEON Biopharma, Inc.’s diluted eps has declined by 939.5% (from $0.38 per share (loss) to $3.95 per share (loss)).
- The most recent figure is from AEON Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: